DISCLAIMER: This page is intended for members of the general public in New Zealand only.

The information provided on this site is intended for general information and education for New Zealand-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified Healthcare Professional.

Information about the NUVAXOVIDTM COVID-19 Vaccine, adjuvanted [SARS-CoV-2 rS (NVX-CoV2373)]

This vaccine has provisional registration in New Zealand for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older as a primary series, 2 dose course or as a booster dose in individuals 18 years of age and older, 6 months after the completion of a primary series. The decision has been made on the basis of short-term efficacy and safety data. Continued registration depends on the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment. The use of this vaccine should be in accordance with official recommendations.

Important information

For more information about the NUVAXOVIDTM COVID-19 Vaccine, adjuvanted [SARS-CoV-2 rS (NVX-CoV2373)], download the Consumer Medicines Information.

Consumer Medicines Information (CMI)
Download PDF

Report an Adverse Event (AE)

To report any adverse events or side effects you can contact the New Zealand Pharmacovigilance Centre (NZPhvC) via their side effect reporting site https://nzphvc.otago.ac.nz/reporting/.

Alternatively, adverse events or side effects can be reported to Novavax Pharmacovigilance at +64 4 974 9419 or via Novavax Adverse Event Reporting Form.

Please do not report the same side effects to multiple systems as all reports will be shared between Novavax and NZPhvC (in an anonymised form) and multiple reports will create unnecessary duplicates.

Contact Us

Tel: +64 4 974 9419
09:00-17:00
Monday - Friday